Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Metabolic disorders, including obesity, diabetes, and cardiovascular disease, are widespread in Westernized nations. Gut microbiota composition is a contributing factor to the susceptibility of an individual to the development of these disorders; therefore, altering a person's microbiota may ameliorate disease. One potential microbiome-altering strategy is the incorporation of modified bacteria that express therapeutic factors into the gut microbiota. For example, N-acylphosphatidylethanolamines (NAPEs) are precursors to the N-acylethanolamide (NAE) family of lipids, which are synthesized in the small intestine in response to feeding and reduce food intake and obesity. Here, we demonstrated that administration of engineered NAPE-expressing E. coli Nissle 1917 bacteria in drinking water for 8 weeks reduced the levels of obesity in mice fed a high-fat diet. Mice that received modified bacteria had dramatically lower food intake, adiposity, insulin resistance, and hepatosteatosis compared with mice receiving standard water or control bacteria. The protective effects conferred by NAPE-expressing bacteria persisted for at least 4 weeks after their removal from the drinking water. Moreover, administration of NAPE-expressing bacteria to TallyHo mice, a polygenic mouse model of obesity, inhibited weight gain. Our results demonstrate that incorporation of appropriately modified bacteria into the gut microbiota has potential as an effective strategy to inhibit the development of metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While human and animal studies have established the ability to successfully populate the oral cavity or gastrointestinal tract with specific strains, combinations of bacteria, or bacteria genetically modified to produce enzymes or metabolites[74,404–407]”
From Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health (2017) · cites this paper as [406]
Experimental — accuracy not yet measuredIn the citing paper
“Chen et al. demonstrated that an N-acylphosphatidylethanolamine (NAPE)-producing strain of EcN could significantly ameliorate symptoms associated with high-fat diet feeding in mice. Mice treated with this recombinant EcN displayed reduced adiposity, insulin resistance, and hepatosteatosis compared to animals treated with an unengineered EcN control37.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785
A core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823
Prevalence and Trends in Obesity Among US Adults, 1999-2008
Flegal, K. M. (2010) · JAMA · doi:10.1001/jama.2009.2014 · Cited by 7,580 · cited 1×
“org Volume 124 Number 8 August 2014 Introduction Obesity dramatically increases the risks for cardiovascular disease and diabetes as well as other diseases, and rates of obesity have increased dramatically in the past 25 years (1, 2).”
Obesity alters gut microbial ecology
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504978102 · Cited by 6,176 · cited 1×
“Changes in global gut microbiota, including an increased ratio of Firmicutes to Bacteroidetes, have been associated with obesity (9, 36–38).”
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., & Burcelin, R. (2008) · Diabetes · doi:10.2337/db07-1403 · Cited by 4,819
Congenital leptin deficiency is associated with severe early-onset obesity in humans
Montague, C. T., Farooqi, I. S., Whitehead, J. P., Soos, M. A., Rau, H., Wareham, N. J., Sewter, C. P., Digby, J. E., Mohammed, S. N., Hurst, J. A., et al. (1997) · Nature · doi:10.1038/43185 · Cited by 2,936 · cited 1×
“However, mutations in these genes are rare in humans and cause extreme forms of obesity (39–41).”
Turnbaugh, P. J., Bäckhed, F., Fulton, L., & Gordon, J. I. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.02.015 · Cited by 2,915
Research works printed but not linked: 3
- Kramer, 1989, Int J Obes., 13, 123
- Wadden, 1989, Int J Obes., 13, 39
- Harris, 2012, J Obes., 2012, 879151
Cited by
Items 101–200 of 288
Gowda, S. G. B., Minami, Y., Gowda, D., Chiba, H., & Hui, S. (2022) · Food Chemistry · doi:10.1016/j.foodchem.2022.133402 · Cited by 43
Evidence for the contribution of the gut microbiome to obesity and its reversal
de Wit, D. F., Hanssen, N. M. J., Wortelboer, K., Herrema, H., Rampanelli, E., & Nieuwdorp, M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg2773 · Cited by 51
“This result relied not only on the observed reduced food intake but also upon an increased resting metabolic rate ( 113 ).”
BackgroundProduction and Sensing of Butyrate in a Probiotic E. coli Strain
Bai, Y., & Mansell, T. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103615 · Cited by 47
“While most probiotic research has focused on the administration of microbes found in nature, some probiotics have been engineered to execute specific therapeutic activities, including delivery of antitumor drugs and insulin for cancer therapy and diabetes [20–22], secretion of antimicrobial peptides [23] and signaling…”
BackgroundTargeting the endocannabinoid system with microbial interventions to improve gut integrity
Jansma, J., Brinkman, F. N., van Hemert, S., & Aidy, S. E. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110169 · Cited by 49
Bhatti, J. S., Thamarai, K., Kandimalla, R., Manczak, M., Yin, X., Kumar, S., Vijayan, M., & Reddy, P. H. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02142-7 · Cited by 41
Engineering the gut microbiota to treat chronic diseases
Dosoky, N. S., Zhang, L., & Davies, S. S. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10771-0 · Cited by 47
“We have engineered EcN to produce higher levels of NAPEs by transforming phosphatidylethanolamine N-acyltransferase (Chen et al. 2014; Dosoky et al. 2018).”
BackgroundMethodSelf-citationWu, H., Chen, J., Guo, S., Deng, J., Zhou, Z., Zhang, X., Qi, T., Yu, F., & Yang, Q. L. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2500099 · Cited by 45
“216 By binding fructose dehydrogenase and mannitol dehydrogenase to glucose transporter proteins encoded by Aeromonas sp., Somabhai et al. found that mice showed an increase in SCFAs and the potent anti-oxidant compound PQQ, which significantly suppressed the elevated level of hepatic triglycerides…”
Mizock, B. A. (2015) · Disease-a-Month · doi:10.1016/j.disamonth.2015.03.011 · Cited by 61
Basson, A. R., Lam, M. C., & Cominelli, F. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2017.08.002 · Cited by 43
Gut microbiota and obesity: an overview of microbiota to microbial-based therapies
Sheykhsaran, E., Abbasi, A., Leylabadlo, H. E., Sadeghi, J., Mehri, S., Mazraeh, F. N., Feizi, H., & Baghi, H. B. (2022) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2021-141311 · Cited by 45
Somabhai, C. A., Raghuvanshi, R., & Nareshkumar, G. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164860 · Cited by 36
Zhang, L., Chen, Z., Dosoky, N. S., Yancey, P. G., Boyd, K. L., Hasty, A. H., Linton, M. F., & Davies, S. S. (2019) · Scientific Reports · doi:10.1038/s41598-018-37373-1 · Cited by 38
Self-citationEngineering chemical interactions in microbial communities
Kenny, D. J., & Balskus, E. P. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00664k · Cited by 42
Metabolic networks of the human gut microbiota
Selber‐Hnatiw, S., Sultana, T., Tse, W., Abdollahi, N., Abdullah, S., Rahbani, J. A., Alazar, D., Alrumhein, N. J., Aprikian, S., Arshad, R., et al. (2019) · Microbiology · doi:10.1099/mic.0.000853 · Cited by 41
Prolonging genetic circuit stability through adaptive evolution of overlapping genes
Chlebek, J. L., Leonard, S. P., Kang-Yun, C. S., Yung, M. C., Ricci, D. P., Jiao, Y., & Park, D. M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad484 · Cited by 37
“For the past several decades, synthetic biologists have sought to genetically engineer microorganisms for a wide range of applications including therapeutics discovery and delivery, drug manufacturing, agricultural yields, biofuel production, mineral extraction, and waste degradation (1-8).”
Advancing therapeutic applications of synthetic gene circuits
Higashikuni, Y., Chen, W. C. W., & Lu, T. K. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.06.011 · Cited by 36
“N-acylphosphatidylethanolamines (NAPEs), immediate precursors of the N-acylethanolamide (NAE) family of lipids, are potent anorexigenic lipids synthesized after feeding that reduce food intake and obesity [49].”
BackgroundBioinspired approaches to encapsulate and deliver bacterial live biotherapeutic products
Brittain, N. Y., & Finbloom, J. A. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115663 · Cited by 37
Role of the microbiome in the normal and aberrant glycemic response
Suez, J., Shapiro, H., & Elinav, E. (2016) · Clinical Nutrition Experimental · doi:10.1016/j.yclnex.2016.01.001 · Cited by 34
“Mice treated with this strain had reduced levels of obesity and insulin resistance [100].”
BackgroundDecoding the microbiome: advances in genetic manipulation for gut bacteria
Chen, Z., Jin, W., Hoover, A., Chao, Y., & Ma, Y. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.05.007 · Cited by 32
Self-citationLiving Therapeutics: The Next Frontier of Precision Medicine
Kelly, V. W., Liang, B. K., & Sirk, S. J. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.0c00444 · Cited by 31
Timmis, K. N., Timmis, K. N., Brüssow, H., & Fernández, L. Á. (2018) · Microbial Biotechnology · doi:10.1111/1751-7915.13355 · Cited by 29
Bhatti, J. S., Tamarai, K., Kandimalla, R., Manczak, M., Yin, X., Ramasubramanian, B., Sawant, N., Pradeepkiran, J. A., Vijayan, M., Kumar, S., et al. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.02.007 · Cited by 30
Gut Microbiome: A New Organ System in Body
Anwar, H., Irfan, S., Hussain, G., Faisal, M. N., Muzaffar, H., Mustafa, I., Mukhtar, I., Malik, S., & Ullah, M. I. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.89634 · Cited by 42
Microbiome Therapeutics: A Path Toward Sustainable Healthcare
Kumar, T., & Chauhan, N. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00010-3 · Cited by 30
Vazquez-Uribe, R., Hedin, K. A., Licht, T. R., Nieuwdorp, M., & Sommer, M. O. A. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.04.021 · Cited by 28
“Looking ahead, researchers and regulatory bodies need to work together in advancing the necessary technology for the safe deployment of AMTs.”
Rutter, J. W., Ozdemir, T., Galimov, E. R., Quintaneiro, L. M., Rosa, L., Thomas, G. M. H., Cabreiro, F., & Barnes, C. P. (2019) · ACS Synthetic Biology · doi:10.1021/acssynbio.9b00166 · Cited by 29
Lim, Y. Y., Lee, Y. S., & Ooi, D. S. Q. (2020) · Biotechnology Journal · doi:10.1002/biot.202000013 · Cited by 29
Sustainable therapies by engineered bacteria
Álvarez, B., & Fernández, L. Á. (2017) · Microbial Biotechnology · doi:10.1111/1751-7915.12778 · Cited by 32
“Engineering of a different probiotic chassis, EcN, has also produced relevant strains with therapeutic effects against IBDs (Whelan et al., 2014) and against obesity (Chen et al., 2014).”
BackgroundAdvancement of Engineered Bacteria for Orally Delivered Therapeutics
Guo, P., Wang, S., Yue, H., Zhang, X., Ma, G., Li, X., & Wei, W. (2023) · Small · doi:10.1002/smll.202302702 · Cited by 30
Bugs, guts and brains, and the regulation of food intake and body weight
Hamilton, M. K., & Raybould, H. E. (2016) · International Journal of Obesity Supplements · doi:10.1038/ijosup.2016.3 · Cited by 30
Biocontainment strategies for in vivo applications of Saccharomyces boulardii
Hedin, K. A., Kruse, V., Vazquez-Uribe, R., & Sommer, M. O. A. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1136095 · Cited by 33
“biomolecules (Arora et al., 2016; Chen et al., 2014; Steidler et al., 2000) or degrade toxic compounds (Isabella et al.”
BackgroundGuo, L., Chen, Z., Amarnath, V., Yancey, P. G., Lenten, B. J. V., Savage, J. R., Fazio, S., Linton, M. F., & Davies, S. S. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.6078 · Cited by 27
“We and others have shown that high-fat diet feeding increases macrophage infiltration and expression of inflammatory genes in the liver (12).”
InfluentialSelf-citationTargeting the gastrointestinal tract to treat type 2 diabetes
Bauer, P. V., & Duca, F. A. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0056 · Cited by 29
“Even more intriguing is the possibility that future treatments may involve genetically modified bacteria that contain therapeutic factors to help treat metabolic disease (Chen et al. 2014).”
BackgroundLive bacterial biotherapeutics in the clinic
Bermúdez‐Humarán, L. G., & Langella, P. (2018) · Nature Biotechnology · doi:10.1038/nbt.4248 · Cited by 26
Engineered Live Biotherapeutics: Progress and Challenges
Tan, Y., Shen, J., Si, T., Ho, C. L., Li, Y., & Dai, L. (2020) · Biotechnology Journal · doi:10.1002/biot.202000155 · Cited by 27
Probiotic Escherichia coli Ameliorates Antibiotic-Associated Anxiety Responses in Mice
Park, K., Park, S.-H., Nagappan, A., Ray, N., Kim, J., Yoon, S., & Moon, Y. (2021) · Nutrients · doi:10.3390/nu13030811 · Cited by 29
“Moreover, EcN has been found to improve microbiota community composition under conditions of metabolic stress [67].”
BackgroundHof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. Ø., & Sommer, M. O. A. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-05108-9 · Cited by 29
“coli Nissle 1917 has been used for many years in clinical settings and could prove to be a good chassis for advanced microbiome therapeutics in the future [11, 50, 56, 57, 58, 59, 60, 61].”
MethodSmall molecule signaling, regulation, and potential applications in cellular therapeutics
McNerney, M. P., & Styczynski, M. P. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1405 · Cited by 28
“Additionally, Lactobacillus gasseri and Escherichia coli have been engineered to deliver therapeutics for diabetes and obesity, respectively.(18,19) While this list is by no means comprehensive (and a more detailed treatment is provided by Mimee et al.”
BackgroundIgarashi, M., Hayakawa, T., Tanabe, H., Watanabe, K., Nishida, A., & Kimura, I. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101649 · Cited by 29
“These results suggest that luminal OEA levels in the large intestine were elevated as a result of feeding, which might cause the accumulation of dietary OEA or the production of OEA by gut microbiota [16,17].”
ResultRecent findings within the microbiota–gut–brain–endocrine metabolic interactome
Obrenovich, M. E., Mana, T. S. C., Rai, H., Shola, D. T. N., Sass, C., McCloskey, B., & Levison, B. S. (2017) · Pathology and Laboratory Medicine International · doi:10.2147/plmi.s121487 · Cited by 24
“The NAPE-producing bacteria acted as a satiety supplement in the study, where the mice drinking the NAPE probiotic in water gained 15% less weight over 12 weeks.(81) This is one example of a therapeutic compound in the gut that may counteract the effects of a high-fat diet.”
A genome-wide screen of bacterial mutants that enhance dauer formation in C. elegans
Khanna, A., Kumar, J., Vargas, M. A., Barrett, L., Katewa, S. D., Li, P. W. F., McCloskey, T., Sharma, A., Naudé, N., Nelson, C. S., et al. (2016) · Scientific Reports · doi:10.1038/srep38764 · Cited by 24
Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents
Ryan, P. M., Patterson, E., Kent, R. M., Stack, H. M., O’Connor, P. M., Murphy, K., Peterson, V. L., Mandal, R., Wishart, D. S., Dinan, T. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14010-x · Cited by 25
Epigenetic Effects of Gut Metabolites: Exploring the Path of Dietary Prevention of Type 1 Diabetes
Theyab, A. A., Almutairi, T., Al-Suwaidi, A. M., Bendriss, G., McVeigh, C., & Châari, A. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.563605 · Cited by 23
A molecular toolkit for heterologous protein secretion across Bacteroides species
Yeh, Y.-H., Kelly, V. W., Pour, R. R., & Sirk, S. J. (2024) · Nature Communications · doi:10.1038/s41467-024-53845-7 · Cited by 26
Barone, M., D’Amico, F., Fabbrini, M., Rampelli, S., Brigidi, P., & Turroni, S. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i41.7041 · Cited by 25
Dosoky, N. S., Guo, L., Chen, Z., Feigley, A. V., & Davies, S. S. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00127 · Cited by 24
Self-citationEndocannabinoids in the treatment of gastrointestinal inflammation and symptoms
Pesce, M., Esposito, G., & Sarnelli, G. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.08.009 · Cited by 23
Development of bacteria as diagnostics and therapeutics by genetic engineering
Lim, D., & Song, M. (2019) · The Journal of Microbiology · doi:10.1007/s12275-019-9105-8 · Cited by 25
Tagliamonte, S., Gill, C. I. R., Pourshahidi, L. K., Slevin, M. M., Price, R. K., Ferracane, R., Lawther, R., O’Connor, G., & Vitaglione, P. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02398-8 · Cited by 25
The beneficial effects of genetically engineered Escherichia coli Nissle 1917 in obese C57BL/6J mice
Ma, J., Wang, J., Xu, L., Liu, Y., & Gu, J. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01073-8 · Cited by 22
“dramatically reduced food intake, insulin resistance, and hepatosteatosis [14].”
BackgroundInfluentialMicrobiome systems biology advancements for natural well-being
Chatterjee, G., Negi, S., Basu, S., Faintuch, J., O’Donovan, A., & Shukla, P. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.155915 · Cited by 24
Gut microbiome: New perspectives for type 2 diabetes prevention and treatment
Li, S.-X., & Guo, Y. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i31.7508 · Cited by 23
Whole genome sequence analysis of the TALLYHO/Jng mouse
Denvir, J., Bošković, G., Fan, J., Primerano, D. A., Parkman, J. K., & Kim, J. H. (2016) · BMC Genomics · doi:10.1186/s12864-016-3245-6 · Cited by 20
“ity and type 2 diabetes [12, 13] and has also served as a model system for many diabetes and obesity related”
BackgroundChoi, B. S.-Y., Daoust, L., Pilon, G., Marette, A., & Tremblay, A. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-0618-3 · Cited by 21
Moriello, A. S., Marzo, V. D., & Petrosino, S. (2022) · Animals · doi:10.3390/ani12030348 · Cited by 29
“Once incorporated into the gut microbiota they exerted a protective function against obesity, provided that a sufficient active anabolic enzyme was present in either the host or engineered bacteria [163,164].”
BackgroundWang, Y., Shi, Y., Peng, X., Li, T., Liang, C., Wang, W., Zhou, M., Yang, J., Cheng, J., Zhang, Z., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303958 · Cited by 22
Rodrigues, J. L., Ferreira, D., & Rodrigues, L. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-08-100741-9.00016-4 · Cited by 19
Al‐Ali, D., Ahmed, A., Shafiq, A., McVeigh, C., Châari, A., Zakaria, D., & Bendriss, G. (2021) · Qatar medical journal · doi:10.5339/qmj.2021.5 · Cited by 22
Engineered Bacteria: General Overview as Therapeutic Agent and a Novel Drug Delivery System
Patil, P. L., Gharat, S. K., Jadhav, K. R., & Kadam, V. J. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201024666221220113517 · Cited by 18
The human gut microbiome – a new and exciting avenue in cardiovascular drug discovery
Du, Y., Li, X., Su, C., Wang, L., Jiang, J., & Hong, B. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1638909 · Cited by 21
Opioid Modulation of the Gut–Brain Axis in Opioid-Associated Comorbidities
Zhang, L., & Roy, S. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a040485 · Cited by 19
Dosoky, N. S., Chen, Z., Guo, Y. P., McMillan, C., Flynn, C. R., & Davies, S. S. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-09958-x · Cited by 20
Self-citationSatapathy, P., Khan, K., Devi, A. T., Patil, A. G., Govindaraju, A. M., Gopal, S., Prasad, M. N. N., More, V. S., Kakarla, R. R., Raghu, A. V., et al. (2019) · Methods in microbiology · doi:10.1016/bs.mim.2019.02.001 · Cited by 19
Iannone, V., Babu, A. F., Lok, J., Gómez-Gallego, C., D’Auria, G., Vazquez-Uribe, R., Vaaben, T. H., Bongers, M., Mikkonen, S. J., Vaittinen, M., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101823 · Cited by 17
“Indeed, recent studies have used genetically engineered E. coli Nissle 1917 to deliver bioactive molecules to induce bene fi cial effects in metabolic disturbances, including obesity [17,18].”
BackgroundLeptogenic effects of NAPE require activity of NAPE-hydrolyzing phospholipase D
Chen, Z., Zhang, Y., Guo, L., Dosoky, N. S., de Ferra, L., Peters, S., Niswender, K. D., & Davies, S. S. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m076513 · Cited by 17
“To verify that pNAE-EcN did not exert a markedly greater effect than pNAPE-EcN in wild-type mice, an identical study to that carried out with Nape-pld mice was performed with male wildtype C57BL/6J mice purchased from the Jackson Laboratory, as described in (4).”
BackgroundMethodInfluentialSelf-citationDesigner probiotics: Opening the new horizon in diagnosis and prevention of human diseases
Debnath, N., Yadav, P., Mehta, P. K., Gupta, P., Kumar, D., Kumar, A., Gautam, V., & Yadav, A. K. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28574 · Cited by 18
“Designer probiotics expressing therapeutic factors that induce the affectability to adipose tissue ‐ derived signals such as leptin may be a potential alternative to counter these metabolic disorders (Chen et al., 2014).”
BackgroundGenetic heterogeneity of engineered Escherichia coli Nissle 1917 strains during scale-up simulation
Munkler, L. P., Mohamed, E. T., Vazquez-Uribe, R., Nissen, V. V., Rugbjerg, P., Worberg, A., Woodley, J. M., Feist, A. M., & Sommer, M. O. A. (2024) · Metabolic Engineering · doi:10.1016/j.ymben.2024.08.001 · Cited by 18
Bendriss, G., Al‐Ali, D., Shafiq, A., Laswi, I., Mhaimeed, N., Salameh, M. A., Burney, Z. A., Pillai, K. V., Châari, A., Zakaria, D., et al. (2020) · Qatar medical journal · doi:10.5339/qmj.2020.47 · Cited by 21
Applying the design-build-test paradigm in microbiome engineering
Pham, H. L., Ho, C. L., Wong, A., Lee, Y. S., & Chang, M. W. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.03.021 · Cited by 17
Beldie, L.-A., Dica, C.-C., Moța, M., Pirvu, B.-F., Burticală, M.-A., Mitrea, A., Clenciu, D., Efrem, I. C., Vladu, B. E., Timofticiuc, D. C. P., et al. (2024) · Nutrients · doi:10.3390/nu16234131 · Cited by 17
Multifaceted Applications of Genetically Modified Micro-organisms: A Biotechnological Revolution
Basarkar, V., Govardhane, S., & Shende, P. K. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220128102823 · Cited by 14
Engineering Diagnostic and Therapeutic Gut Bacteria
Landry, B. P., & Tabor, J. J. (2018) · ASM Press eBooks · doi:10.1128/9781555819705.ch14 · Cited by 13
Chen, J., Lin, Y., Li, T., Zhu, H., Huang, F., Yang, C., & Guo, F. (2022) · Food & Function · doi:10.1039/d1fo04358g · Cited by 13
Treatment of insulin resistance: straight from the gut
Zhang, X., Zheng, X., & Yuan, Y. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.016 · Cited by 13
Are TallyHo Mice A True Mouse Model for Type 2 Diabetes and Alzheimer’s Disease?
Ramasubramanian, B., & Reddy, P. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190613 · Cited by 13
“While only the male mice develop hyperglycemia in this model, the females do exhibit obesity and the female TH mice have been used to study nondiabetic obesity [59, 67].”
BackgroundEllermann, M. (2023) · Advances in Drug and Alcohol Research · doi:10.3389/adar.2023.11359 · Cited by 13
“These results corresponded with increased hepatic NAE levels, decreased lipid accumulation and in fl ammation markers in the liver, and improved metabolic parameters such as glucose tolerance and insulin sensitivity [88].”
BackgroundResultRole of the Endocannabinoidome in Human and Mouse Atherosclerosis
Piscitelli, F., & Silvestri, C. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190826162735 · Cited by 13
Therapeutic manipulation of the microbiome in liver disease
Parthasarathy, G., Malhi, H., & Bajaj, J. S. (2024) · Hepatology · doi:10.1097/hep.0000000000000987 · Cited by 15
Jain, S., Shukla, A. K., DEEPIKA, D., Panwar, S., Kumari, A., Yadav, A. K., & Kumar, A. (2024) · Food Bioengineering · doi:10.1002/fbe2.12098 · Cited by 11
Mehmood, K., Moin, A., Hussain, T., Rizvi, S. M. D., Gowda, D., Shakil, S., & Kamal, M. (2021) · Folia Microbiologica · doi:10.1007/s12223-021-00926-5 · Cited by 12
“Further, efforts to boost generation of anti-inflammatory NAPEs (N-acyl phosphatidylethanolamines) have been successful in treating obesity and cardiometabolic disease in animal models (Chen et al. 2014; May-Zhang et al. 2019).”
BackgroundSynthetic receptors to understand and control cellular functions
Chang, H., & Bonnet, J. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.11.011 · Cited by 14
Gao, X., Sun, Y., Yang, Y., Yang, X. X., Liu, Q., Guo, X., Wu, L., & Wang, Q. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142250 · Cited by 13
Lomis, S. W. N. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000577 · Cited by 10
“Genus Prevotella ↓ T1DM ↓ T2D Anti-inflammatory ↓ Mucin [22,23,74,229,235,237]”
Direct Modulation of the Gut Microbiota as a Therapeutic Approach for Alzheimer’s Disease
Wang, Y., & Dykes, G. A. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210806165751 · Cited by 8
Application of Bacterial Whole-Cell Biosensors in Health
Song, Y., Rampley, C. P. N., Chen, X., Du, F., Thompson, I. P., & Huang, W. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-23217-7_136 · Cited by 10
Ahuja, A., Dhanalekshmi, U. M., Saraswathy, M. P., Nandakumar, S., Francis, A. P., & Gurpreet, K. N. (2022) · Drug Metabolism and Bioanalysis Letters · doi:10.2174/2949681015666220615120300 · Cited by 9
Nutraceuticals from Bioengineered Microorganisms
Singh, B., Mal, G., Gautam, S. K., & Mukesh, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-21309-1_6 · Cited by 9
Overview of microbial therapeutics in immunological disorders
Mishra, R., Mohanty, S., Mahapatra, S., & Prasad, P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99336-4.00008-2 · Cited by 8
Host—microbial interactions in metabolic diseases: from diet to immunity
Lee, J.-H., & Park, J. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-2087-y · Cited by 7
“GLP-1 can decrease food intake, attenuate weight gain, improve glucose homeostasis, and reduce hepatic triglyceride levels (Agarwal et al., 2014; Chen et al., 2014; Duan et al., 2015; Lin et al., 2016; May-Zhang et al., 2019).”
BackgroundSynthetic symbiotic bacteria reduces the toxicity of mercury ingested via contaminated food
Chen, X., Chi, J., Liu, Y., Du, R., Guo, M., & Xu, W. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.113937 · Cited by 8
Pro and prebiotics foods that modulate human health
Pop, O., Socaci, S., Suharoschi, R., & Vodnar, D. (2019) · The Role of Alternative and Innovative Food Ingredients and Products in Consumer Wellness · doi:10.1016/b978-0-12-816453-2.00010-3 · Cited by 6
Research and application of intelligent diagnosis and treatment engineering bacteria
Zhao, N., Chen, J., Shi, J., Gao, Y., Li, L., & Dong, L. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1524376 · Cited by 7
Singh, B., & Mal, G. (2016) · Journal of Gastrointestinal & Digestive System · doi:10.4172/2161-069x.1000415 · Cited by 7
Recombinant Probiotics and Microbiota Modulation as a Good Therapy for Diseases Related to the GIT
de Jesus, L. C. L., Lima, F. A., Coelho-Rocha, N. D., da Silva, T. F., Paz, J., Azevedo, V., Mancha-Agresti, P. D. C., & Drumond, M. M. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.88325 · Cited by 7
Redesign of ultrasensitive and robust RecA gene circuit to sense DNA damage
Chen, J. X., Lim, B., Steel, H., Song, Y., Ji, M., & Huang, W. E. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13767 · Cited by 8
“, 2019), obesity (Chen et al., 2014) and various cancer treatments (Ganai et al.”
Advances in microbial decorations and its applications in drug delivery
He, T., Zhao, Z., Luo, Z., Jia, W. P., Zhang, J., Zhao, Y., Xiao, W., Ming, Z., & Chen, K. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0036 · Cited by 10
“For example, Chen et al. [94] incorporated transgenic bacteria secreted N-acylphosphatidylethanolamines (ape) into the gut microbiota to provide continuous treatment for chronic diseases and obesity, thus reducing the need for daily continuous administration of therapeutic compounds.”
BackgroundBioinformatics for Human Microbiome
Ghosh, A., Firdous, S., & Saha, S. (2021) · Springer eBooks · doi:10.1007/978-981-33-6191-1_17 · Cited by 6
Liu, Y., Dong, J., Zhang, Z., Liu, Y., & Wang, Y. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.877937 · Cited by 7
“They also found higher expression of genes encoding fatty acid oxidation in the gut microbiome, and reduced infiltration of monocytes/macrophages into liver (Chen et al., 2014).”
BackgroundFrom covalent bonds to eco-physiological pharmacology of secondary plant metabolites
Chatterjee, S. S. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.037 · Cited by 7
New Perspectives on the Development of Antiobesity Drugs
Costantino, L., & Barlocco, D. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.167 · Cited by 5
Metadata
- Authors
- Chen, Z., Guo, L., Zhang, Y., L. Walzem, R., Pendergast, J. S., Printz, R. L., Morris, L. C., Matafonova, E., Stien, X., Kang, L., Coulon, D., McGuinness, O. P., Niswender, K. D., & Davies, S. S.
- Affiliations
- Vanderbilt University (US)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Davies, Sean S.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-06-24
- Volume
- 124
- Issue
- 8
- Pages
- 3391-3406
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4109548
- OpenAlex
- W2076877166
- Cited by
- 277
- References
- 76
- Citations by year
- 2026: 12 · 2025: 11 · 2024: 19 · 2023: 22 · 2022: 31 · 2021: 26 · 2020: 26 · 2019: 22 · 2018: 18 · 2017: 35 · 2016: 29 · 2015: 23 · 2014: 3
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Funders
- National Institutes of Health (1dp2od003137-01, 5p60dk020593-31)
- National Institute of Diabetes and Digestive and Kidney Diseases (P60-DK020593, U24DK092993, DK59637, DK 20593, U24DK059637, P30DK058404, P30DK020593)
- National Center for Research Resources (UL1RR024975)
- National Center for Complementary and Integrative Health (R01AT007830, AT07830)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- obesity, gut microbiota, engineered bacteria, N-acylphosphatidylethanolamine, Escherichia coli Nissle 1917, high-fat diet, dietary intake, insulin resistance, hepatic steatosis, metabolic disorders, microbiome engineering
- MeSH terms
- Acyltransferases, Animals, Digestive System, Disease Models, Animal, DNA-Binding Proteins, Eating, Escherichia coli, Female, Humans, Liver, Male, Mice, Inbred C57BL, Obesity, Phosphatidylethanolamines, Recombinant Proteins, Weight Gain, Arabidopsis Proteins, Mice, Diet, High-Fat, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.